Results 181 to 190 of about 51,191 (308)

Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches. [PDF]

Cancers (Basel)
Ou Y, Wei H, Peng C, Li J, Wei K, Zhan C, Zhang Z.   +6 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

A murine model of sepsis induces age- and sex-specific chromatin remodeling in myeloid-derived suppressor cells. [PDF]

Front Immunol
Charles AM, Rodhouse CE, Darden DB, Gauthier ML, Zhou M, Hernandez-Rios M, Wang D, Casadesus G, Bible L, Mohr AM, Xiao F, Cai G, Brant JO, Wallet SM, Mathews CE, Moldawer LL, Chakrabarty P, Bacher RL, Efron PA, Maile R, Kladde MP.   +20 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Spatial heterogeneity of MDSCs mediated by ANXA1-FPRs signaling drives immune suppression in OSCC progression. [PDF]

Nat Commun
Li F, Han Y, Ou F, Deng L, Li H, Yu X, Yi Y, Ma R, Wu Z, You Z, Chen H.   +10 more
europepmc   +1 more source

SLPI/FBW7/c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

Cancer Science, EarlyView.
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen, Xin Li, Weixiong Zhu, Yanxi Mu, Guoqing Zhang, Youheng Zhang, Yusheng Cheng, Wence Zhou   +7 more
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. [PDF]

Wiley Interdiscip Rev Nanomed Nanobiotechnol
He Y, Yeo Y.
europepmc   +1 more source

Advancements in Inorganic Chiral Nanomaterials for Anti‐Tumor Immunotherapy

Cancer Science, EarlyView.
Schematic illustration of how inorganic chiral nanomaterials enhance immune activation to promote tumor cell elimination through targeted delivery, immunogenic cell death, and immune microenvironment modulation. ABSTRACT While the past decade has witnessed unprecedented technological advancements, cancer remains a major health threat, with conventional
Siyu Chen, Qian Tang, Xiqian Chen, Yinghao Liang, Jin Qiu, Yongmei Liao, Changqiang Li, Hongru Yu, Fang Xie, Zongjunlin Liu   +9 more
wiley   +1 more source

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts. [PDF]

Cancer Immunol Immunother
Suzuki R, Watanabe S, Shono K, Masuda T, Yanai K, Yamazaki R, Ando Y, Wakabayashi T, Tanaka S, Sekiya T, Kushiro K, Yanagimura N, Sato M, Tanaka T, Nozaki K, Saida Y, Hokari S, Arita M, Ohashi R, Shima K, Kimura Y, Aoki N, Ohshima Y, Koya T, Kikuchi T.   +24 more
europepmc   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source